Galectin Therapeutics clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of patients in the belapectin treatment groups who develop new esophageal varices at 78 weeks [18 months] of treatment compared to placebo. After: Measure: Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo.

Check registry source